Sanofi Acquires Dynavax Technologies for $2.2 Billion to Enhance Vaccine Portfolio

Sanofi has announced its agreement to acquire Dynavax Technologies Corp. for approximately $2.2 billion, marking a significant move to bolster its vaccines division, which is primarily known for its flu shot franchise. The acquisition involves a cash payment of $15.50 per share, representing a 39% premium over Dynavax’s closing stock price prior to the announcement. This strategic purchase aims to enhance Sanofi’s offerings in adult immunization by adding Dynavax’s hepatitis B vaccine, which is already marketed in the United States, and an experimental shingles vaccine currently undergoing early human trials.

CityLabSanofi to buy Dynavax for US$2.2 billion to add shingles vaccine

Sanofi has stated that this acquisition is not expected to affect its financial guidance for the year 2025. The company anticipates completing the transaction in the first quarter of 2026, positioning itself to expand its vaccine portfolio without immediate financial repercussions.

Sanofi to buy Dynavax for US$2.2 billion to add shingles vaccine

The announcement of the acquisition coincided with a setback for Sanofi, as the U.S. Food and Drug Administration (FDA) rejected its experimental multiple sclerosis drug, tolebrutinib. This decision was described by Houman Ashrafian, head of research and development at Sanofi, as a "significant and meaningful change" from previous feedback received from the FDA. The company expressed disappointment and indicated its commitment to collaborating with the FDA to navigate future steps for the drug.

CityLab

While the acquisition is positioned as a growth opportunity for Sanofi, some analysts may question the timing of the deal, given the recent FDA rejection of a key drug. Concerns may arise regarding the strategic focus of Sanofi, especially in light of setbacks in its drug development pipeline.

CityLab

Sanofi has reiterated its commitment to expanding its vaccine portfolio through this acquisition, emphasizing the importance of enhancing its presence in adult immunization. The company has also expressed its disappointment regarding the FDA's decision on tolebrutinib, highlighting the need for further dialogue with regulatory bodies.

CityLab

Looking ahead, Sanofi will focus on finalizing the acquisition of Dynavax Technologies and integrating its products into its existing vaccine offerings. Additionally, the company will seek to address the challenges posed by the FDA's recent decision regarding its multiple sclerosis drug, aiming for a clearer path forward in its drug development efforts.

CityLab